small molecule

BYSANTI

MILSAPERIDONE

Loss of exclusivityMay 2044latest FDA-listed patent expiry

CompanyVanda Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	BYSANTI
Active ingredient	MILSAPERIDONE
Strength	6MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	February 2026
Marketing status	RX

Listed patents

Patent	Expires	Type
12478619	May 2044	use U-4434
9074254	December 2031	use U-4436
9074256	February 2031	use U-4437
9072742	January 2031	use U-4437
9074255	December 2030	use U-4436
8999638	October 2030	use U-4437
12606869	September 2030	use U-4507
10563259	July 2030	use U-4437
9157121	April 2030	use U-4436
10570453	March 2028	use U-4436

Regulatory exclusivity

Code	Expires
NCE	February 2031

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Vanda Pharmaceuticals